XBiotech Inc. (XBIT): Price and Financial Metrics
GET POWR RATINGS... FREE!
XBIT POWR Grades
- Value is the dimension where XBIT ranks best; there it ranks ahead of 58.11% of US stocks.
- XBIT's strongest trending metric is Growth; it's been moving up over the last 169 days.
- XBIT ranks lowest in Momentum; there it ranks in the 5th percentile.
XBIT Stock Summary
- The ratio of debt to operating expenses for XBIOTECH INC is higher than it is for about only 0.51% of US stocks.
- Equity multiplier, or assets relative to shareholders' equity, comes in at 1.03 for XBIOTECH INC; that's greater than it is for merely 5.84% of US stocks.
- Revenue growth over the past 12 months for XBIOTECH INC comes in at -57.16%, a number that bests just 3.19% of the US stocks we're tracking.
- If you're looking for stocks that are quantitatively similar to XBIOTECH INC, a group of peers worth examining would be PTGX, RNA, CRSP, NRIX, and ENTA.
- XBIT's SEC filings can be seen here. And to visit XBIOTECH INC's official web site, go to www.xbiotech.com.
XBIT Valuation Summary
- In comparison to the median Healthcare stock, XBIT's price/earnings ratio is 111.64% lower, now standing at -2.7.
- Over the past 93 months, XBIT's EV/EBIT ratio has gone up 34.5.
Below are key valuation metrics over time for XBIT.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| XBIT | 2022-11-25 | 11.8 | 0.4 | -2.7 | 3.2 |
| XBIT | 2022-11-23 | 12.0 | 0.4 | -2.7 | 3.1 |
| XBIT | 2022-11-22 | 12.1 | 0.4 | -2.8 | 3.1 |
| XBIT | 2022-11-21 | 12.3 | 0.4 | -2.8 | 3.1 |
| XBIT | 2022-11-18 | 12.6 | 0.4 | -2.9 | 3.0 |
| XBIT | 2022-11-17 | 12.9 | 0.4 | -2.9 | 3.0 |
XBIT Growth Metrics
- Its 5 year net income to common stockholders growth rate is now at 1378.37%.
- Its 4 year cash and equivalents growth rate is now at 603.71%.
- Its 4 year net income to common stockholders growth rate is now at 1378.37%.
The table below shows XBIT's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 8.21 | -19.286 | -36.164 |
| 2022-06-30 | 11.049 | -16.661 | -26.767 |
| 2022-03-31 | 14.044 | 62.513 | -20.241 |
| 2021-12-31 | 18.394 | 69.445 | -17.414 |
| 2021-09-30 | 19.163 | 70.813 | -12.785 |
| 2021-06-30 | 25.193 | 81.698 | -12.05 |
XBIT's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- XBIT has a Quality Grade of D, ranking ahead of 11.91% of graded US stocks.
- XBIT's asset turnover comes in at 0.071 -- ranking 289th of 682 Pharmaceutical Products stocks.
- QLGN, GTHX, and CPHI are the stocks whose asset turnover ratios are most correlated with XBIT.
The table below shows XBIT's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.071 | 0.391 | -0.195 |
| 2021-03-31 | 0.102 | 0.248 | -0.138 |
| 2020-12-31 | 0.124 | 0.215 | -0.116 |
| 2020-09-30 | 0.082 | 0.166 | 7.794 |
| 2020-06-30 | 0.070 | 0.188 | 10.040 |
| 2020-03-31 | 0.039 | 0.237 | 14.665 |
XBIT Stock Price Chart Interactive Chart >
XBIT Price/Volume Stats
| Current price | $3.05 | 52-week high | $13.12 |
| Prev. close | $3.10 | 52-week low | $3.00 |
| Day low | $3.05 | Volume | 22,000 |
| Day high | $3.19 | Avg. volume | 75,092 |
| 50-day MA | $3.55 | Dividend yield | N/A |
| 200-day MA | $5.87 | Market Cap | 92.84M |
XBiotech Inc. (XBIT) Company Bio
XBiotech Inc. is a clinical-stage biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various different diseases. The company was founded in 2005 and is based in Austin, Texas.
Latest XBIT News From Around the Web
Below are the latest news stories about XBIOTECH INC that investors may wish to consider to help them evaluate XBIT as an investment opportunity.
XBiotech Third Quarter 2022 Earnings: US$0.42 loss per share (vs US$0.11 loss in 3Q 2021)XBiotech ( NASDAQ:XBIT ) Third Quarter 2022 Results Key Financial Results Net loss: US$12.7m (loss widened by 288% from... |
Insiders own 35% of XBiotech Inc. (NASDAQ:XBIT) shares but individual investors control 47% of the companyIf you want to know who really controls XBiotech Inc. ( NASDAQ:XBIT ), then you'll have to look at the makeup of its... |
XBiotech Announces First Patient Enrolled into the French National Cancer Institute (INCA) Sponsored Phase I/II/III Clinical Study for Natrunix™ Therapy for Colorectal CancerINCA funded Phase I/II/III Study for Natrunix in Combination with Trifluridine/Tipiracil, the TASKIN Study, Launches at 20 Leading Medical Centers in FranceAUSTIN, Texas, Oct. 13, 2022 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced today the enrollment of the first patient in a multicenter, randomized clinical study for Natrunix in combination with trifluridine/tipiracil for the treatment of colorectal cancer. The much anticipated clinical study for XBiotech’s candidate cancer treatment i |
XBiotech (NASDAQ:XBIT) shareholders have endured a 73% loss from investing in the stock a year agoAs every investor would know, you don't hit a homerun every time you swing. But it would be foolish to simply accept... |
We Think XBiotech (NASDAQ:XBIT) Can Afford To Drive Business GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
XBIT Price Returns
| 1-mo | -13.11% |
| 3-mo | -23.94% |
| 6-mo | -48.91% |
| 1-year | -75.83% |
| 3-year | -73.46% |
| 5-year | -26.33% |
| YTD | -72.60% |
| 2021 | -28.88% |
| 2020 | -16.15% |
| 2019 | 267.42% |
| 2018 | 28.93% |
| 2017 | -61.07% |
Loading social stream, please wait...